Investor Relations
Aug 07, 2018
OPKO Health Reports Second Quarter 2018 Financial Results MORE >>
Aug 03, 2018
OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children MORE >>
Aug 02, 2018
OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018 MORE >>
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>

SEC Filing Details

Document Details

Form
Filing Date
May 4, 2018
Document Date
May 3, 2018
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
OPKO Health, Inc.
Filer
FROST PHILLIP MD ET AL